Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APACT: Adjuvant nab-Paclitaxel + Gemcitabine in Pancreatic Cancer
NCT01964430Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Mar 2014
- Primary completion
- Jun 2022
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 21
01
Overview
A Phase 3 trial of nab-paclitaxel in pancreatic ductal adenocarcinoma (PDAC), sponsored by Celgene Corporation. Started Mar 2014; status: completed.
02
Drugs
nab-paclitaxel
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01964430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01964430.